Jason Sterling, PhD
About Jason Sterling, PhD
Jason Sterling, PhD, serves as the Director of Gene Therapy Analytics at Precision BioSciences, Inc., where he specializes in Chemistry, Manufacturing, and Controls Analytical Development. He has extensive experience in the biopharmaceutical sector, having held various senior scientific roles at companies such as GSK Vaccines, Catalent Pharma Solutions, and Biolex Therapeutics.
Current Role at Precision BioSciences
Jason Sterling, PhD, serves as the Director of Gene Therapy Analytics at Precision BioSciences, Inc. since 2021. He is based in Durham, North Carolina. In this role, he focuses on Chemistry, Manufacturing, and Controls Analytical Development (CMC-AD) within the field of gene therapy analytics. His work involves developing analytical methods specifically for adeno-associated virus (AAV) therapies, emphasizing analytical Quality by Design (aQbD).
Previous Experience in Biopharmaceuticals
Prior to his current position, Jason Sterling held several significant roles in the biopharmaceutical industry. He worked as a Senior Scientist at GSK Vaccines from 2015 to 2017, where he specialized in separation and sizing. He also served as a Principal Scientist and Project Director at Catalent Pharma Solutions from 2017 to 2021, focusing on analytical and formulation resources. His experience includes roles at Biolex Therapeutics and Liquidia Technologies, contributing to his extensive background in drug development.
Educational Background in Life Sciences
Jason Sterling earned his Ph.D. in Biochemistry and Molecular Biology from The University of Georgia, where he studied from 1996 to 2004. He also holds a Bachelor of Science degree in Biology from McGill University, completed between 1992 and 1996. His educational foundation has equipped him with the knowledge and skills necessary for his roles in the biopharmaceutical sector.
Expertise in Analytical Strategies
Jason Sterling possesses expertise in designing innovative analytical strategies that support drug development programs. His focus on analytical methods and Quality by Design principles plays a crucial role in advancing gene therapy projects. His extensive experience in various scientific roles has contributed to his ability to drive analytical development in the biopharmaceutical industry.